Drugs & Targets FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer March 14, 2025Vol.51 No.10
Clinical Roundup CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study March 07, 2025Vol.51 No.09
Clinical Roundup Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera March 07, 2025Vol.51 No.09
Guest Editorial Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology February 28, 2025Vol.51 No.08By Harpreet Singh
In Brief Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president February 28, 2025Vol.51 No.08
Drugs & Targets FDA accepts review for odronextamab BLA in r/r follicular lymphoma February 28, 2025Vol.51 No.08
Clinical Roundup First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai February 21, 2025Vol.51 No.07
